US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 0.679
- +0.027+4.13%
Close Aug 23 16:00 ET
- 0.690
- +0.011+1.58%
Post 19:38 ET
27.67MMarket Cap-196P/E (TTM)
0.683High0.657Low296.41KVolume0.660Open0.652Pre Close199.02KTurnover1.00%Turnover RatioLossP/E (Static)40.74MShares5.62052wk High-0.37P/B20.19MFloat Cap0.64152wk Low--Dividend TTM29.74MShs Float71.500Historical High--Div YieldTTM3.94%Amplitude0.641Historical Low0.671Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
BioXcel Therapeutics Stock Forum
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
NEWS
BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
BioXcel Therapeutics (Nasdaq: BTAI) has announced that Dr. Rob Risinger will present both oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting from May 28 to 31 in Miami Beach, FL. The presentations will focus on the comparison of sublingual Dexmedetomidine wit...
NEWS
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
The late-breaking abstract on preliminary findings from the Phase 2 trial of BXCL701 and KEYTRUDA® in metastatic pancreatic ductal adenocarcinoma has been selected for presentation at the 2024 ASCO Annual Meeti...
No comment yet